ArticlePharmacoEconomics2014
Avoiding and identifying errors and other threats to the credibility of health economic models.
Article in PharmacoEconomics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- A Systematic Review of Reporting of Validation Efforts for Cancer Health Economic Decision Models.PharmacoEconomics · 2026Pooled it
- Digitally enabled therapy for chronic tic disorders and Tourette Syndrome: a systematic review and economic evaluation.Health technology assessment (Winchester, England) · 2026Pooled it
- The effects and safety of testosterone replacement therapy for men with hypogonadism: the TestES evidence synthesis and economic evaluation.Health technology assessment (Winchester, England) · 2024Pooled it
- Automated devices for identifying peripheral arterial disease in people with leg ulceration: an evidence synthesis and cost-effectiveness analysis.Health technology assessment (Winchester, England) · 2024Pooled it
- Biomarkers for assessing acute kidney injury for people who are being considered for admission to critical care: a systematic review and cost-effectiveness analysis.Health technology assessment (Winchester, England) · 2022Pooled it
- The UK resuscitative endovascular balloon occlusion of the aorta in trauma patients with life-threatening torso haemorrhage: the (UK-REBOA) multicentre RCT.Health technology assessment (Winchester, England) · 2024Trial
- [Use of suture closure systems in interventional electrophysiology : Impact on workflows, resource utilization, reimbursement, and patient safety in hospitals in the STYLE AF study].Herzschrittmachertherapie & Elektrophysiologie · 2026Article
- Assessment and predictive analysis of health professions students' proficiency in health economics and pharmacoeconomics in Southwest China: a cross-sectional study.BMC medical education · 2024Article
- A structured process for the validation of a decision-analytic model: application to a cost-effectiveness model for risk-stratified national breast screening.Applied health economics and health policy · 2024Article
- Four Aspects Affecting Health Economic Decision Models and Their Validation.PharmacoEconomics · 2022Article
- TECH-VER: A Verification Checklist to Reduce Errors in Models and Improve Their Credibility.PharmacoEconomics · 2019Article
- Model Structuring for Economic Evaluations of New Health Technologies.PharmacoEconomics · 2018Review
- Implementing parallel spreadsheet models for health policy decisions: The impact of unintentional errors on model projections.PloS one · 2018Article
- Replicating Health Economic Models: Firm Foundations or a House of Cards?PharmacoEconomics · 2017Article
- Verification of Decision-Analytic Models for Health Economic Evaluations: An Overview.PharmacoEconomics · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Health economic models have become the primary vehicle for undertaking economic evaluation and are used in various healthcare jurisdictions across the world to inform decisions about the use of new and existing health technologies. Models are required because a single source of evidence, such as a randomised controlled trial, is rarely sufficient to provide all relevant information about the expected costs and health consequences of all competing decision alternatives. Whilst models are used to synthesise all relevant evidence, they also contain assumptions, abstractions and simplifications. By their very nature, all models are therefore 'wrong'. As such, the interpretation of estimates of the cost effectiveness of health technologies requires careful judgements about the degree of confidence that can be placed in the models from which they are drawn. The presence of a single error or inappropriate judgement within a model may lead to inappropriate decisions, an inefficient allocation of healthcare resources and ultimately suboptimal outcomes for patients. This paper sets out a taxonomy of threats to the credibility of health economic models. The taxonomy segregates threats to model credibility into three broad categories: (i) unequivocal errors, (ii) violations, and (iii) matters of judgement; and maps these across the main elements of the model development process. These three categories are defined according to the existence of criteria for judging correctness, the degree of force with which such criteria can be applied, and the means by which these credibility threats can be handled. A range of suggested processes and techniques for avoiding and identifying these threats is put forward with the intention of prospectively improving the credibility of models.
Indexed as
Identifiers
25027943What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.